In this regard, a new clinical trial (NCT05921760) is evaluating the efficacy of combining ivosidenib, nivolumab, and ipilimumab in previously treated patients with non-resectable or metastatic IDH1 mutant CCA. This evidence concerns the gene IDH1 and cholangiocarcinoma.